TY - JOUR
AR - JICOA-2019-2-101
TI - Therapeutic Design of Peptide Modulators of the Interaction Between eNOS and
p53 in Atherosclerosis
AU - Araújo, DS
AU - Assunção , LP
AU - Barbosa , AM
AU - Costa, IR
AU - de Curcio, JS
AU - Moraes, D
AU - Oliveira, LN
AU - Santos, TG
AU - Silva, CTX
AU - Silva, KSF
AU - Silva, MG
JO - Journal of Integrative Cardiology Open Access
PY - 2019
DA - Fri 10, May 2019
SN - 2674-2489
DO - http://dx.doi.org/10.31487/j.JICOA.2019.02.01
UR - https://www.sciencerepository.org/therapeutic-design-of-peptide-modulators-of-the-interaction-between-enos-and-p53-in-atherosclerosis_JICOA-2019-2-101 
KW - eNOS, p53, atherosclerosis, PPI, interface of interaction, modulating peptides
AB - Atherosclerosis is a cardiovascular disease featuring a chronic inflammation due to the accumulation of
lipids within the tunica intima of arteries. The development of the disease depends on dynamic changes in
the vascular biology. Immune system cells directly influence the pathogenesis of atherosclerosis during the
inflammatory process. Currently, atherosclerosis diagnosis is performed by non-invasive or invasive
methods depending on the type of arteries that are being investigated. New diagnostic and therapeutic
procedures should improve the quality of life of patients. Some of the genes that could be biomarkers of
cardiovascular diseases are TP53 and eNOS. The protein p53 is recognized as a tumor suppressor protein
that controls DNA repair, cell cycle progression or arrest and apoptosis. These functions that p53 exerts are
well known and some other functions are being investigated, such as its role in the cardiovascular system.
The eNOS gene regulates the levels of nitric oxide, which is vital for several intracellular biological
functions, such as vasodilation, vascular homeostasis, protection of arteries against injuries, cellular growth,
signaling pathways and immune response among others. Here, we used an in-silico approach to predict four
models of interaction between clinically important proteins (eNOS and p53), to predict the interface of
interaction and to rationally design modulating peptides to be tested in vitro and in vivo and possibly used
as a therapeutic agent.